How have the shares performed?
Brooklyn ImmunoTherapeutics Inc. (BTX) saw downtrend of -7.81% in the recent trading with $21.60 being its most recent. The current price level -73.22% lower than the highest price of $80.67 marked by the stock while trading over the past 52-weeks, whereas it is 1048.94% higher than the lowest price of $1.88 the company dropped to over past 52-weeks. The latest news story on BTX appeared in Business Wire under the title “Brooklyn ImmunoTherapeutics Announces Publication of Results of IRX-2 Monotherapy in Early Stage Breast Cancer in Breast Cancer Research” on May-11-21.
Squeezing the time span to 30 day period shows us the stock is currently trading -73.22% below one month high and is +259.40% above of the lowest during that time.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform.
Brooklyn ImmunoTherapeutics Inc. Earnings – What Happened With BTX
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. During the reported three-month period, company’s sales were $1.18 billion.
BTX – Brooklyn ImmunoTherapeutics Inc. Stock Earnings Estimates
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 1.48 million. BTX does have institutional investors; and they hold 0.20% of the stock.
Brooklyn ImmunoTherapeutics Inc. – Insider Activity and Holdings
Moreover, the latest SEC filings also revealed that stock came across 0 new insider purchases involving 0 shares. On the other hand, BTX declared 21,608 shares have been sold in 12 insider transactions over the past three months.
Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, current ratio recorded by Brooklyn ImmunoTherapeutics Inc. was 0.73 while posting a debt to equity ratio of 2.22. The count was 62.59 for long-term debt to equity ratio.
Technical Analysis of Brooklyn ImmunoTherapeutics Inc. (AMEX:BTX) stock